Serum cholecystokinin concentrations in dogs with naturally acquired pituitary-dependent hyperadrenocorticism.
OBJECTIVE To determine serum cholecystokinin (CCK) concentrations in dogs with pituitary-dependent hyperadrenocorticism (PDH) and to evaluate associations among CCK concentration, PDH, and gallbladder mucocele (GBM). ANIMALS 14 client-owned dogs with PDH and 14 healthy dogs. PROCEDURES Dogs were separated into 4 groups: healthy dogs without gallbladder sludge (group A; n = 7), healthy dogs with gallbladder sludge (group B; 7), dogs with PDH and gallbladder sludge (group C; 8), and dogs with PDH and GBM (group D; 6). Serum CCK concentrations were then measured before and 1, 2, and 4 hours after consumption of a high-fat meal. Concentrations in dogs with PDH were also measured before and after trilostane treatment. Results were compared among groups and assessment points. RESULTS Preprandial serum CCK concentrations in group C were significantly lower than those in groups A, B, and D, but no significant differences in postprandial CCK concentrations were identified among the groups 1, 2, or 4 hours after the meal. With respect to trilostane treatment of dogs with PDH, no significant differences were identified between pre- and post-trilostane serum CCK concentrations in group C or D. Median CCK concentration after trilostane treatment was higher in group D than in group C, but this difference was not significant. CONCLUSIONS AND CLINICAL RELEVANCE The outcomes in this study did not support the hypothesis that a low circulating CCK concentration affects the development of GBM in dogs with PDH.
Sungjun
S
Noh
Hye-Sun
HS
Kim
Jinhwa
J
Chang
Ji-Houn
JH
Kang
Dongwoo
D
Chang
Mhan-Pyo
MP
Yang
D000308:Adrenocortical Hyperfunction / Q000097:blood / Q000662:veterinary*; D000818:Animals; D016022:Case-Control Studies; D002766:Cholecystokinin / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D013196:Dihydrotestosterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D004283:Dog Diseases / Q000097:blood* / Q000000981:diagnostic imaging / Q000188:drug therapy; D004285:Dogs; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D005705:Gallbladder Diseases / Q000097:blood / Q000662:veterinary; D006854:Hydrocortisone / Q000097:blood; D008297:Male
D004791:Enzyme Inhibitors; D013196:Dihydrotestosterone; D002766:Cholecystokinin; D002784:Cholesterol; C009954:trilostane; D006854:Hydrocortisone